Supportive care in hematological malignancies: Hematopoietic growth factors, infections, transfusion therapy

Current Opinion in Hematology

Volumn 6, Issue 4, 1999, Pages 262-273

  Fetscher, Sebastian ^a   Mertelsmann, Roland ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CISAPRIDE; COUMARIN; CYCLOSPORIN A; DIGOXIN; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 11; ITRACONAZOLE; KERATINOCYTE GROWTH FACTOR; KETOCONAZOLE; MACROLIDE; MEVINOLIN; MICONAZOLE; PHENYTOIN; PYRROLE DERIVATIVE; RIFAMPICIN; THROMBOPOIETIN;

ANTIBIOTIC THERAPY; BLOOD DYSCRASIA; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG INHIBITION; HEALTH CARE COST; HUMAN; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LIFE SUPPORT CARE; PLATELET TRANSFUSION;

EID: 0032814191     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199907000-00011     Document Type: Review

References (80)

1. Fetscher S, Mertelsmann R: Supportive care in hematological malignancies, including hematopoietic growth factors, transfusions, and antimicrobial therapy. Curr Opin Hematol 1997, 4:248-255.
2. Fetscher S, Mertelsmann R: Supportive care in hematological malignancies. Curr Opin Hematol 1998, 5:271-286.
3. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practise guidelines. J Clin Oncol 1994, 12:2471-2508.
4. Update of American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practise guidelines. J Clin Oncol 1996, 14:1957-1960.
5. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of myeloid leukemia. Blood 1996, 88:3675-3685.
6. Johnson PRE, Liu Yin JA: The role of granulocyte- and granulocyte-macrophage-colony stimulating factors in the treatment of acute myeloid leukemia. Br J Haematol 1997, 97:1-8.
7. Sousa AB, Fernandes JP, Costa G, Ferreira G, Nunes O, Ribeiro P, et al.: Granulocyte-macrophage-colony stimulating factor in post-remission therapy of acute myeloid leukemia. Hematol Cell Ther 1998, 40:63-66.
8. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JAL, Papa G, et al., for the International Acute Myeloid Leukemia Study Group: A randomized, double- blind, placebo-controlled phase III study of filgrastim in remission induction and consolidation chemotherapy for adults with de novo acute myeloid leukemia. Blood 1997, 89:4710-4718.
9. Löwenberg B, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeck A, Vellenga E, et al.: Value of different modalities of granulocyte-colony stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997, 15:3496-3506.
10. Witz F, Sadoun A, Perrin MD, Berthou C, Briere J, Cahn JY, et al.: A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myeloid leukemia in elderly patients. Blood 1998, 91:2722-2730.
11. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, et al., and the Southwest Oncology Group: A double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 1998, 91:3607-3615.
12. Chouaid C, Bassinet L, Fuhrmann C, Monnet I, Housset B: Routine use of colony-stimulating factors is not cost effective and dose not increase patient comfort in the treatment of small cell lung cancer: an analyzes using a Markov model. J Clin Oncol 1998, 16:2700-2707.
13. Tjan-Heijinen VCG, Biesma B, Festen J, Splinter TAW, Cox A, Wagener TDJ, Postmus PE: Enhancing myelotoxicity due to granulocyte colony-stimulating factor until 48 hours before next chemotherapy course in patients in patients with small cell lung carcinoma. J Clin Oncol 1998, 16:2708-2714.
14. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradinin P, Falda M, et al.: G-CSF administration following peripheral blood progenitor cell autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998, 21:401-407.
15. Lee SM, Radford JA, Dobson L, Huq T, Ryder WDJ, Pettengell R, et al.: Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgin's lymphoma: clinical benefits at no extra costs. Br J Cancer 1998, 77:1294-1299.
16. 2) in the setting that occurs after high-dose chemotherapy and autotransplantation.
17. Stahel RA, Jost L, Honegger H, Betts E, Goebel ME, Nagler A: Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997, 15:1730-1735.
18. Lyman GH, Kuderer N, Greene J, Balducci L: The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998, 34:1857-1864.
19. Kaushansky K: Thrombopoietin. N Engl J Med 1998, 339:746-754. This is a brilliantly written, comprehensive review on the biology and clinical experience with TPO as of September 10, 1998. However, it does not cover the withdrawal of PEG-MGDF, which occurred on September 11, 1998. Interestingly, and further to the credit of this lucid presentation, it contains several cautionary remarks as to the potential of immunological reactions to both TPO and its derivatives.
20. Mijayzaki H: Update on thrombopoietin in preclinical and clinical trials. Curr Opin Hematol 1998, 5:197-202.
21. Nichol JL: Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol 1998, 5:203-208.
22. Vadhan-Raj S: Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol 1998, 100:261-268.
23. Press release. Thousand Oaks: Amgen, Inc.; September 11, 1998.
24. Adams JA, Yin JAL, Bereton ML, Briggs M, Burgess R, Hyde K: The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMDGF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute leukemia. Br J Haematol 1997, 99:139-146.
25. Catani L, Gugliotta L, Campanini E, Mangianti S, Gibellini D, Baravelli S, et al.: Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CH34+ cells show a distinct phenotype and responsiveness to interteukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). Br J Haematol 1998, 100:207-218.
26. Fanucci M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W. et al.: Effects of polyethylen glycol-conjugated human megakaryocyte growth and development factor on platelet counts of patients after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409.
27. Geissler K, Kabrna E, Stengg S, Schwarzinger I, Knöbl P, Valent P, et al.: Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukemia. Br J Haematol 1998, 102:535-543.
28. Maslak P, Nimer SD: The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. Semin Hematol 1998, 33:24-29.
29. Williams JL, Pipia G, Fatta NS, Long MW: Thrombopoietin requires additional megakaryocyte-active cytokines for optimal ex vivo expansion of megakaryocyte precursor cells. Blood 1998, 91:4118-4126.
30. Hermann JA, Hall MA, Maini Rn, Feldmann M, Brennan FM: Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis and Rheum 1998, 41:1388-1397.
31. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr Brinson YS, et al.: Interleukin-11 promotes T-cell polarization and prevents acute graft-versus- hst disease after allogeneic bone marrow transplantation. J Clin Invest 1998, 102:115-123.
32. Fiore NF, Ledniczki G, Liu Q, Orazi A, Du X, Williams DA, Grosfeld JL: Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg 1998, 33:24-29.
33. Waxman AB, Einarsson O, Seres T, Knickelbein RG, Warshaw JB, Johnston R, et al.: Targeted lung-expression of interleukin-11 enhances murine tolerance of 100% oxygen and dimished hyperoxia-induced DNA fragmentation. J Clin Invest 1998, 101:1970-1982.
34. Hill PA, Tumber A, Papaioannou S, Meikie MC: The cellular interactions of interleukin-11 on bone resorption in vitro. Endocrinology 1998, 139:1564-1572.
35. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T: Suppression of interleukin-11-mediated bone resorption by cyclooxygenase inhibitors. J Cell Physiol 1998, 175:247-254.
36. Zhang Y, Fujita N, Oh-hara T, Morinaga Y, Nakagawa T, Yamada M, Tsuruo T: Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene 1998, 16:693-703.
37. Yi EY, Williams ST, Lee H, Malicki DM, Chin EM, Yin S, et al.: Keratinocyte growth factor ameliorates radiation and bleomycin-induced lung injury and mortality. Am J Pathol 1996, 149:1963-1970.
38. Ulich TR, Whitcomb L, Tang W, O'Conner Tressel P, Tarpley J, Yi EY: Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Cancer Res 1997, 57:472-475.
39. Yi EY, Williams ST, Lee H, Malicki DM, Chin EM, Yin S, et al.: Keratinocyte growth factor ameliorates radiation and bleomycin-induced lung injury and mortality. Am J Pathol 1996, 149:1963-1970.
40. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, et al.: Keratinocyte growth factor protects mice from chemotherapy and radiation- induced gastrointestinal injury and mortality. Cancer Res 1998, 58:933-939.
41. Khan WB, Shui C, Ning S, Knox SJ: Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res 1997, 148:248-253.
42. Playford RJ, Marchbank T, Mandir N, Highham A, Meeren K, Ghatei M, et al.: Effects of keratinocyte growth factor on gut growth and repair. J Pathol 1998, 184:316-322.
43. Gniadiecki R: Regulation of keratinocyte proliferation. Gen Pharmacol 1998, 30:619-622.
44. Ning S, Shui C, Khan WB, Benson W, Lacey DL, Knox SJ: Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vivo and in vitro. Int J Radiat Oncol Biol Phys 1998, 40:177-187.
45. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al.: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997, 25:551-573. These guidelines remain the number one referral source for the management of infectious problems in hematology and oncology in 1998.
46. Silvestri F, Baccarani M: Hepatitis C virus-related lymphomas. Br J Haematol 1997, 99:475-480.
47. Andreone P, Zignegno AL, Cursaro C, Gramenzi A, Ghelinzoni F, Fiorino S, et al.: Prevalence of monoclonal gammopathies in patients with hepatitis C infections. Ann Intern Med 1998, 129:294-298.
48. Scully RE, Mark EJ, McNeely WF, Ebeling SH: Case records of the Massachusets General Hospital: case 3-1999. N Engl J Med 1999, 340:300-307.
49. Luppi M, Longo G, Ferrari MG, Barozzi P, Marasca M, Morselli M, et al.: Clinico-pathological characterization of hepatitis C virus-related B-cell non- Hodgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol 1998,9:495-498.
50. Silvestri F, Barillari G, Fanin R, Salmaso F, Pipan C, Falasca E, et al.: Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmocytoid lymphoma/immunocytoma. Ann Oncol 1998, 9:499-504.
51. Trepo C, Berthillon P, Vivitski L: HCV and lymphoproliferative disorders. Ann Oncol 1998, 9:469-470.
52. Heuft HG, Berg T, Schreier E, Künkel U, Tacke M, Schwella N, et al.: Epidemiological and clinical aspects of hepatitis G virus infection in blood donors and immunocomprised recipients of HGF-contamined blood. Vox Sang 1998, 74:161-167.
53. Mauser-Bunschoten EP, Damen M, Zaaijer HL, Sjeps M, Rosendaal G, Lelie PN, et al.: Hepatitis G virus RNA and hepatitis G virus-E2 antibodies in Dutch hemophilia patients in relation to transfusion history. Blood 1998, 92:2164-2168.
54. Keenan RD, Harrison P, Joffre L, Skidmoe SJ, Collingham KE, Pillay D, Milligan DW: Hepatitis G virus and lymphoproliferative disorders. Br J Haematol 1997, 99:706-713.
55. Anaissie EJ, Konotyiannnis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ: Infections in patients with chronic lymphocytic leukamia treated with fludarabinee. Ann Intern Med 1998, 129:559-566.
56. Richardson MD, Kokki MH: Antifungal therapy in "bone marrow failure." Br J Haematol 1998, 100:619-628. This is a comprehensive, up-to-date overview of antifungal strategies in the neutropenic host.
57. de Pauw BE, Meis JFGM: Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer 1998, 6:31-38. This is a brief and refreshingly critical overview of antifungal strategies in patients with hematological malignancies.
58. Johansen HK, Gotzsche PC: Meta-analysis of prophylcatic or empirical anti-fungal therapy in cancer patients with neutropenia. Top Support Care Oncol 1998, 26:9-10.
59. Kern W, Braess J, Bertz H, Pott C, Schleyer E, Finke J, et al.: Chronic systemic aspergillosis in a patient with acute myeloid leukemia. Ann Hematol 1998, 76:175-177.
60. Reichenberger F, Habicht J, Kaim A, Dalquen P, Benet F, Schlapfer P, et al.: Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematological diseases. Am J Respir Crit Care Med 1998, 158:885-890.
61. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al.: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15:139-147.
62. Lamy T, Bernard M, Courtois A, Jacquelined C, Chevrier S, Dauriac C, et al.: Prophylactic use of itraconazole for the prevention of IPA in high risk neutropenic patients. Leuk Lymphoma 1998, 30:163-174.
63. Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, et al.: Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol 1997, 99:331-336.
64. Maury S, Leblanc T, Feuilhade M, Molina JM, Schaison G: Sucesssful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis 1998, 26:200-202.
65. Mahal M, Saiman L, Bitmann L, Weitzman I, Grossman M, Dembitzer F, et al.: Review of trichosporonosis with a report of a case of disseminated trichosporon asahii infection. Infect Dis Clin Pract 1998, 7:175-179. This is a succinct and clinically useful "mini-review" of this rare fungal infection.
66. Kataoka-Nishimura S, Akiyama H, Saku K, Kashiwa M, Mori S, Tanikawa S, et al.: Invasive infection due to trichosporon cutaneum in patients with hematological malignancies. Cancer 1998, 82:484-487.
67. Sweet D, Reid M: Disseminated neotale trichosporon beigelli infection: successful treatment with liposomal amphotericin B. J Infect 1998, 36: 120-121.
68. Leenders ACAP, Daenen S, Jansen RLH, Hop WCJ, Lowenberg B, Wijermans PW, et al.: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia- associated invasive fungal infections. Br J Haematol 1998, 103:205-212.
69. Coukell AJ, Brogden RN: Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998, 55:585-612. This is a comprehensive and balanced assessment of in vitro, animal, and human data on the use of liposomal amphotericin B in aspergillosis, candidiasis, leishmaniasis, and other infections.
70. Albengres E, Le Louet H, Tillement JP: Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998, 18:83-97. This is a thorough yet practical summary of an often underestimated topic. It is mandatory study material for all pharmacologists and infectious disease consultants dealing with the use of antifungal agents in hematology departments.
71. Maesaki S, Kohno S, Kaku M, Koga H, Hara K: Effects of antifungal agent combinations administered simultaneously and sequentially against aspergillus fumigatus. Antimicrob Agents Chemother 1994, 38:2843-2485.
72. Martin E, Maier F, Bhadi S: Antagonistic effects of fluconazole and 5-flucytosine on candicidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994, 38:1331-1338.
73. Schaffner A, Böhler A: Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993, 36:421-424.
74. Karthaus M, Huebnes G, Elser C, Geissler RG, Heil G, Ganser A, et al.: Detection of chronic systemic canidida infection in leukaemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation. Eur J Haematol 1998, 60:320-321.
75. Norol F, Bierling P, Rooudot-Thoraval F, Le Coeur FF, Rieux C, Lavaux A, et al.: Platelet transfusions: a dose-response study. Blood 1998, 92:1448-1453.
76. 9 trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998, 91:3601-3606.
77. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP: Randomized study of prophylactic platelet transfusions threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J ClinOncol 1997, 15:1143-1149.
78. Contreras M: Consensus conference on platelet transfusion: 27 and 18 November 1997: final statement. Leukemia 1998, 12:1330-1331.
79. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevrau C, et al.: A risk model for thrombocytopenia requiring platelet transfusions after cytotoxic chemotherapy. Blood 1998, 92:405-410.
80. Bernstein SH, Nadamanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, et al.: A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998, 91:3509-3517.